NYSE: NEUENeuehealth Inc Stock
$6.40-0.12 (-1.84%)
Updated Apr 17, 2025
NEUE Price
$6.40
Fair Value Price
N/A
Market Cap
$55.39M
52 Week Low
$3.79
52 Week High
$7.66
P/E
-0.28x
P/B
-0.04x
P/S
0.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$936.66M
Earnings
-$134.68M
Gross Margin
20.8%
Operating Margin
-12.1%
Profit Margin
-19.9%
Debt to Equity
-0.69
Operating Cash Flow
-$123M
Beta
1.32
Next Earnings
May 2, 2025
Ex-Dividend
N/A
Next Dividend
N/A
NEUE Overview
Bright Health Group, Inc. offers health insurance through two segments, NeueHealth and Bright HealthCare. NeueHealth delivers virtual and in-person clinical care services to patients under contracts through its owned and affiliated primary care clinics. Bright HealthCare offers commercial and medicare health plan products to consumers in 14 states. Bright Health was incorporated in 2016 and is headquartered in Minneapolis, MN.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NEUE's potential to beat the market
- NEUE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Plan
Industry Rating
A
NEUE
RankedUnranked of 10
RankedUnranked of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $330.13 | B | |
| $60.70 | B | |
| $454.11 | B |
Be the first to know about important NEUE news, forecast changes, insider trades & much more!
NEUE News
Overview
Due Diligence Score
–
Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NEUE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NEUE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NEUE is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
NEUE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NEUE due diligence checks available for Premium users.
Valuation
NEUE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.28x
Industry
24.78x
Market
27.98x
NEUE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.04x
Industry
2.6x
NEUE's financial health
Profit margin
Revenue
$232.6M
Net Income
-$2.7M
Profit Margin
-6.9%
NEUE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NEUE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$544.4M
Liabilities
$930.5M
Debt to equity
-0.69
NEUE's short-term liabilities ($710.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NEUE's short-term assets ($434.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NEUE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NEUE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.4M
Investing
-$2.3M
Financing
-$14.3M
NEUE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NEUE vs Healthcare Plan Stocks
Neuehealth Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.